Skip to main content

Advertisement

Log in

Incidence of deepening of the upper eyelid sulcus on treatment with a tafluprost ophthalmic solution

  • Clinical Investigation
  • Published:
Japanese Journal of Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

Deepening of the upper eyelid sulcus (DUES), one symptom of prostaglandin-associated periorbitopathy, was recently found to be an additional side effect of prostaglandin-related ophthalmic solutions. Here, we prospectively investigated the incidence and factors associated with DUES in Japanese open-angle glaucoma patients initially treated with benzalkonium chloride (BAK)-preserved tafluprost (TAF).

Methods

In this open-label prospective study instilling TAF in one eye, mean deviation (MD) and intraocular pressure (IOP) were measured, and facial photographs and subjective reports of DUES were obtained at intervals over 6 months. Three ophthalmologists independently assessed the photographs of DUES and reached consensus. Relationships between demographic and ocular/systemic factors (age, sex, MD, refraction and IOP reduction) and DUES occurrence were evaluated.

Results

Forty-three eyes of 43 glaucoma patients (24 men and 19 women) were evaluated. Mean IOP before treatment was 16.6 ± 2.7 and after treatment, 14.1 ± 2.3 mmHg (P < 0.001). The objective rate of DUES was 9 % (4/43) at 2 months, 14 % (6/43) at 4 months and 14 % (6/43) at 6 months. During this period, only one patient self-reported an occurrence of DUES. No significant association was found between DUES occurrence and any of the demographic, ocular, or systemic factors.

Conclusions

Physicians should inform patients about DUES as a minor side effect when prescribing TAF for IOP control.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Bean GW, Camras CB. Commercially available prostaglandin analogs for the reduction of intraocular pressure: similarities and differences. Surv Ophthalmol. 2008;53(Suppl 1):S69–84.

    Article  PubMed  Google Scholar 

  2. Pantcheva MB, Seibold LK, Awadallah NS, Kahook MY. Tafluprost: a novel prostaglandin analog for treatment of glaucoma. Adv Ther. 2011;28:707–15.

    Article  CAS  PubMed  Google Scholar 

  3. Alm A, Grierson I, Shields MB. Side effects associated with prostaglandin analog therapy. Surv Ophthalmol. 2008;53(Suppl 1):S93–105.

    Article  PubMed  Google Scholar 

  4. http://www.aao.org/pdf/Glaucoma-2011-Syllabus.pdf. Accessed 5 July 2013.

  5. Peplinski LS, Albiani Smith K. Deepening of lid sulcus from topical bimatoprost therapy. Optom Vis Sci. 2004;81:574–7.

    Article  PubMed  Google Scholar 

  6. Filippopoulos T, Paula JS, Torun N, Hatton MP, Pasquale LR, Grosskreutz CL. Periorbital changes associated with topical bimatoprost. Ophthalmic Plast Reconstr Surg. 2008;24:302–7.

    Article  Google Scholar 

  7. Yam JC, Yuen NS, Chan CW. Bilateral deepening of upper lid sulcus from topical bimatoprost therapy. J Ocul Pharmacol Ther. 2009;25:471–2.

    Article  CAS  PubMed  Google Scholar 

  8. Tappeiner C, Perren B, Iliev ME, Frueh BE, Goldblum D. Orbital fat atrophy in glaucoma patients treated with topical bimatoprost—can bimatoprost cause enophthalmos? Klin Monbl Augenheilkd. 2008;225:443–5.

    Article  CAS  PubMed  Google Scholar 

  9. Yang HK, Park KH, Kim TW, Kim DM. Deepening of eyelid superior sulcus during topical travoprost treatment. Jpn J Ophthalmol. 2009;53:176–9.

    Article  CAS  PubMed  Google Scholar 

  10. Aihara M, Shirato S, Sakata R. Incidence of deepening of the upper eyelid sulcus after switching from latanoprost to bimatoprost. Jpn J Ophthalmol. 2011;55:600–4.

    Article  PubMed  Google Scholar 

  11. Maruyama K, Shirato S, Tsuchisaka A. Incidence of deepening of the upper eyelid sulcus after topical use of travoprost ophthalmic solution in Japanese. J Glaucoma. 2012. doi:10.2147/OPTH.S47783.

  12. Ung T, Currie ZI. Periocular changes following long-term administration of latanoprost 0.005%. Ophthalmic Plast Reconstr Surg. 2011. doi:10.1097/IOP.0b013e31821d86a5.

  13. Inoue K, Shiokawa M, Wakakura M, Tomita G. Deepening of the upper eyelid sulcus caused by 5 types of prostaglandin analogs. J Glaucoma. 2013;22:626–31.

    Article  PubMed  Google Scholar 

  14. Nakajima T, Matsugi T, Goto W, Kageyama M, Mori N, Matsumura Y, et al. New fluoroprostaglandin F(2alpha) derivatives with prostanoid FP-receptor agonistic activity as potent ocular-hypotensive agents. Biol Pharm Bull. 2003;26:1691–5.

    Article  CAS  PubMed  Google Scholar 

  15. Uusitalo H, Pillunat LE, Ropo A. Efficacy and safety of tafluprost 0.0015 % versus latanoprost 0.005 % eye drops in open-angle glaucoma and ocular hypertension: 24-month results of a randomized, double-masked phase III study. Acta Ophthalmol. 2010;88:12–9.

    Article  CAS  PubMed  Google Scholar 

  16. Schnober D, Hofmann G, Maier H, Scherzer ML, Ogundele AB, Jasek MC. Diurnal IOP-lowering efficacy and safety of travoprost 0.004 % compared with tafluprost 0.0015 % in patients with primary open-angle glaucoma or ocular hypertension. Clin Ophthalmol. 2010;4:1459–63.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  17. Nakano T, Yoshikawa K, Kimura T, Suzumura H, Nanno M, Noro T. Efficacy and safety of tafluprost in normal-tension glaucoma with intraocular pressure of 16 mmHg or less. Jpn J Ophthalmol. 2011;55:605–13.

    Article  CAS  PubMed  Google Scholar 

  18. Erb C, Lanzl I, Seidova SF, Kimmich F. Preservative-free tafluprost 0.0015% in the treatment of patients with glaucoma and ocular hypertension. Adv Ther. 2011;28:575–85.

    Article  PubMed  Google Scholar 

  19. Chabi A, Varma R, Tsai JC, Lupinacci R, Pigeon J, Baranak C, et al. Randomized clinical trial of the efficacy and safety of preservative-free tafluprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2012;153:1187–96.

    Article  CAS  PubMed  Google Scholar 

  20. Chaudhary O, Adelman RA, Shields MB. Predicting response to glaucoma therapy in one eye based on response in the fellow eye: the monocular trial. Arch Ophthalmol. 2008;126:1216–20.

    Article  PubMed  Google Scholar 

  21. Dayanir V, Cakmak H, Berkit I. The one-eye trial and fellow eye response to prostaglandin analogues. Clin Experiment Ophthalmol. 2008;36:136–41.

    Article  PubMed  Google Scholar 

  22. Sakata R, Shirato S, Miyata K, Aihara M. Recovery from deepening of the upper eyelid sulcus after switching from bimatoprost to latanoprost. Jpn J Ophthalmol. 2013;57:179–84.

    Article  PubMed  Google Scholar 

  23. Park J, Cho HK, Moon JI. Changes to upper eyelid orbital fat from use of topical bimatoprost, travoprost, and latanoprost. Jpn J Ophthalmol. 2011;55:22–7.

    Article  CAS  PubMed  Google Scholar 

  24. Casimir DA, Miller CW, Ntambi JM. Preadipocyte differentiation blocked by prostaglandin stimulation of prostanoid FP2 receptor in murine 3T3-L1 cells. Differentiation. 1996;60:203–10.

    Article  CAS  PubMed  Google Scholar 

  25. Miller CW, Casimir DA, Ntambi JM. The mechanism of inhibition of 3T3-L1 preadipocyte differentiation by prostaglandin F2alpha. Endocrinology. 1996;137:5641–50.

    CAS  PubMed  Google Scholar 

  26. Serrero G, Lepak NM. Prostaglandin F2alpha receptor (FP receptor) agonists are potent adipose differentiation inhibitors for primary culture of adipocyte precursors in defined medium. Biochem Biophys Res Commun. 1997;233:200–2.

    Article  CAS  PubMed  Google Scholar 

  27. Strong P, Coleman RA, Humphrey PP. Prostanoid-induced inhibition of lipolysis in rat isolated adipocytes: probable involvement of EP3 receptors. Prostaglandins. 1992;43:559–66.

    Article  CAS  PubMed  Google Scholar 

Download references

Conflicts of interest

R. Sakata, None; S. Shirato, None; K. Miyata, None; M. Aihara, None.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Rei Sakata.

About this article

Cite this article

Sakata, R., Shirato, S., Miyata, K. et al. Incidence of deepening of the upper eyelid sulcus on treatment with a tafluprost ophthalmic solution. Jpn J Ophthalmol 58, 212–217 (2014). https://doi.org/10.1007/s10384-013-0299-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10384-013-0299-8

Keywords

Navigation